Valuation: NetraMark Holdings Inc.

Market Cap 5.49Cr 3.93Cr 3.52Cr 3.24Cr 2.94Cr 373.78Cr 5.58Cr 39Cr 15Cr 195.62Cr 15Cr 14Cr 619.57Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 5.49Cr 3.93Cr 3.52Cr 3.24Cr 2.94Cr 373.78Cr 5.58Cr 39Cr 15Cr 195.62Cr 15Cr 14Cr 619.57Cr EV / Sales 2026 *
137x
EV / Sales 2027 * -
Free-Float
89.17%
Yield 2026 *
-
Yield 2027 * -
10/09 NetraMark Holdings Inc Publishes Peer-Reviewed Study Demonstrating NetraAI Uncovers Clinical Trial Signals Missed By Conventional AI And Foundation Models CI
01/09 Netramark Holdings Inc. Announces Appointment of Keith M. Fournier to Board of Directors CI
14/08 NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 CI
09/07 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
09/07 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
29/06 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
29/06 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
15/05 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
08/05 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
04/05 NetraMark Holdings Inc. Announces Executive Changes CI
22/04 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
20/04 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
09/04 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
1 day+5.45%
1 week-1.69%
Current month-19.44%
1 month-14.71%
3 months-25.64%
6 months-35.56%
Current year-47.27%
1 week 0.48
Extreme 0.48
0.6
1 month 0.48
Extreme 0.48
0.76
Current year 0.48
Extreme 0.48
1.28
1 year 0.48
Extreme 0.48
1.29
3 years 0.16
Extreme 0.155
1.8
5 years 0.15
Extreme 0.15
1.97
10 years 0.15
Extreme 0.15
3.17
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Date Insider Type Main position Quantity % Market Cap. Importance
23/09/26 Buy

Chairman

10,000 0.0108%
23/09/26 Buy

Chairman

25,000 0.0270%
23/09/26 Buy

Chairman

25,000 0.0270%
Change 5-day change 1-year change 3-year change Capi.($)
+5.45%-1.69%-54.33%+46.84% 3.91Cr
-0.86%+0.97%-2.85%+55.97% 3,94400Cr
-1.61%-1.27%-2.57%+1,218.62% 47TCr
-4.81%+9.28%-50.17%+34.96% 44TCr
-4.66%+6.11%+73.42%+215.74% 32TCr
-3.18%+8.65%+89.56%+492.20% 27TCr
-1.09%-3.00%-6.87%+66.32% 27TCr
-26.74%-29.55%-39.34%-2.72% 16TCr
-21.97%-21.75%+60.72%+140.33% 13TCr
-5.28%+2.13%+68.74%+227.36% 10TCr
Average -6.49%+3.37%+13.63%+249.56% 61.06TCr
Weighted average by Cap. -2.72%+1.70%+3.35%+176.06%

Financials

2026 *2027 *
Net sales 4L 3L 3L 2L 2L 2.73Cr 4L 28.27L 11.28L 1.43Cr 10.76L 10.53L 4.53Cr -
Net income - -
Net Debt - -
Projected Income Statement - Annual - NetraMark Holdings Inc.
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume
28/26/28 CA$0.5800 +5.45% 32,300
27/26/27 CA$0.5500 +5.77% 7,601
23/26/23 CA$0.5200 +4.00% 1,34,300
22/26/22 CA$0.5000 -15.25% 1,01,708
21/26/21 CA$0.5900 0.00% 68,400

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - NetraMark Holdings Inc.
  1. Stock Market
  2. Stocks
  3. AIAI Stock